Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Notifiable interest in securities

3 Apr 2009 13:24

RNS Number : 1163Q
China Real Estate Opportunities PLC
03 April 2009
 



3 April 2009

China Real Estate Opportunities plc 

Notifiable interest in securities 

The Board of China Real Estate Opportunities plc ("CREO" or the "Company") announces that on 2 April 2009, the Company was notified by Treasury Holdings (which is owned as to 50 per cent. by Richard Barrett, a director and significant shareholder of the Company, and as to 50 per cent. by John Ronan, a significant shareholder of the Company) that the following transactions have been undertaken in the ordinary shares of the Company. 

Treasury Holdings has disposed of 661,000 ordinary shares to Treasury Properties Limited. 

Treasury Holdings has disposed of 2,000,000 ordinary shares to Jasbay Properties Limited.

420,653 ordinary shares held by Treasury Holdings in trust for Treasury Holdings China Limited have been transferred to Treasury Holdings China Limited.

Treasury Holdings China Limited has disposed of 420,653 ordinary shares to Treasury Properties Limited.

In addition the Company was notified on 2 April 2009 by Real Estate Opportunities Limited that they have disposed of 8,387,941 ordinary shares, in equal amounts, to four wholly owned subsidiaries being Real Estate Opportunities Holdings Limited, REO (CREO Holdings) No.1 Limited, REO (CREO Holdings) No.2 Limited and REO (CREO Holdings) No.3 Limited. 

All the above transactions were undertaken at a price of £2.175 per ordinary share.

There is no change in the ultimate beneficial ownership of these ordinary shares. The Concert Party (as defined in the Notice of Extraordinary General Meeting) remain interested in 25,973,984 ordinary shares, representing 54.96 per cent of the Company's issued share capital. 

Contact: 

CREO 

Ray Horney, Chairman 

Tel: + 44 (0) 1273 775 225 

 

Sarah Moriarty, Investor Relations 

Tel: + 353 1 618 9455 

Matrix Corporate Capital LLP 

Paul Fincham, Rob Naylor 

Tel: + 44 (0) 20 3206 7000 

Davy 

Des Carville 

Tel: + 353 1 679 6363 

Bankside Consultants 

Simon Rothschild, Oliver Winters 

Tel: + 44 (0) 20 7367 8888 

Murray Consultants 

Ed Micheau 

Tel: + 353 1 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUOUURKURSRAR
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.